Why William Kennedy Unloaded 25,071 Shares of TG Therapeutics, Inc. (TGTX)?; Evertec (EVTC)’s Sentiment Is 0.97

June 19, 2018 - By mmahotstuff

EVERTEC, Inc. (NYSE:EVTC) Logo

Sentiment for Evertec Inc (EVTC)

Evertec Inc (EVTC) investors sentiment increased to 0.97 in Q1 2018. It’s up 0.11, from 0.86 in 2017Q4. The ratio has increased, as 71 funds increased and opened new holdings, while 73 sold and decreased stock positions in Evertec Inc. The funds in our database now have: 57.60 million shares, up from 55.60 million shares in 2017Q4. Also, the number of funds holding Evertec Inc in top ten holdings increased from 1 to 2 for an increase of 1. Sold All: 21 Reduced: 52 Increased: 40 New Position: 31.

More notable recent TG Therapeutics, Inc. (NASDAQ:TGTX) news were published by: Seekingalpha.com which released: “TG Therapeutics: An Immunology Powerhouse” on June 14, 2018, also Nasdaq.com with their article: “TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab in Patients with ..” published on June 18, 2018, Nasdaq.com published: “TG Therapeutics, Inc. Presents Phase 2 Data Evaluating Umbralisib in CLL Patients Intolerant to Prior BTK or PI3K ..” on June 18, 2018. More interesting news about TG Therapeutics, Inc. (NASDAQ:TGTX) were released by: Globenewswire.com and their article: “TG Therapeutics, Inc. Appoints Adam Waldman as Chief Commercial Officer” published on June 04, 2018 as well as Nasdaq.com‘s news article titled: “TG Therapeutics, Inc. Announces Clinical and Preclinical Data Presentations at the 23rd Congress of the European ..” with publication date: June 15, 2018.

William Kennedy is the shareholder of Tg Therapeutics Inc. He a few days ago made a sale of 25,071 shares in the corporation with the deal value amounting to approximately $337,205 U.S Dollars. This number is according to the revealed price of $13.5 a share. The regulatory filing shows that William Kennedy now has in hand exactly 0.08% of the New York-based company’s market cap

Analysts await TG Therapeutics, Inc. (NASDAQ:TGTX) to report earnings on August, 8. They expect $-0.55 earnings per share, down 22.22% or $0.10 from last year’s $-0.45 per share. After $-0.59 actual earnings per share reported by TG Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -6.78% EPS growth.

Since December 29, 2017, it had 0 insider buys, and 2 insider sales for $609,256 activity. 32,006 shares were sold by Power Sean A, worth $272,051 on Friday, December 29. KENNEDY WILLIAM JAMES had sold 25,071 shares worth $337,205 on Thursday, June 14.

Investors sentiment decreased to 1.46 in Q1 2018. Its down 0.54, from 2 in 2017Q4. It turned negative, as 11 investors sold TG Therapeutics, Inc. shares while 30 reduced holdings. 29 funds opened positions while 31 raised stakes. 37.47 million shares or 6.47% more from 35.20 million shares in 2017Q4 were reported. 58,421 were accumulated by Dupont. Cubist Systematic Strategies Ltd has 12,376 shares. 39,736 were reported by Price T Rowe Assocs Md. The Pennsylvania-based Vantage Inv Ltd Company has invested 0% in TG Therapeutics, Inc. (NASDAQ:TGTX). Morgan Stanley accumulated 158,116 shares. 464,391 are owned by Highland Cap Mgmt Lp. State Street Corporation reported 0% in TG Therapeutics, Inc. (NASDAQ:TGTX). Hanson Mcclain Incorporated stated it has 62 shares. Manufacturers Life Insurance Communications The invested 0% in TG Therapeutics, Inc. (NASDAQ:TGTX). Wells Fargo And Mn holds 0% or 39,535 shares. Putnam Limited Liability Co holds 0% or 92,543 shares. Guggenheim Capital Ltd Llc reported 74,974 shares stake. Grp One Trading Lp has 181,477 shares for 0.02% of their portfolio. Opaleye Incorporated has 274,200 shares. Macquarie Group Incorporated Ltd invested in 52,224 shares.

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. The company has market cap of $1.07 billion. It develops TG-1101 , a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-Hodgkin??s lymphoma and chronic lymphocytic leukemia. It currently has negative earnings. The firm also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies.

The stock increased 0.73% or $0.1 during the last trading session, reaching $13.8. About 867,228 shares traded. TG Therapeutics, Inc. (NASDAQ:TGTX) has risen 14.71% since June 19, 2017 and is uptrending. It has outperformed by 2.14% the S&P500. Some Historical TGTX News: ; 21/05/2018 – TG Therapeutics Presenting at Conference Jun 4; 18/04/2018 – TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Company’s BET Inhibitor, TG-1601, at the 2018 American Association for Cancer Research (AACR) Annual Meeting; 08/03/2018 – TG Therapeutics 4Q Loss/Shr 46c; 24/04/2018 – TG Therapeutics’ Ublituximab (TG-1101) Treats Patients With Multiple Sclerosis; 08/05/2018 – TG THERAPEUTICS INC – QTRLY SHR LOSS $0.59; 24/04/2018 – TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab (TG-1101) in Patients with Multiple Sclerosis at the American Academy of Neurology 70th Annual Meeting; 08/03/2018 – TG Therapeutics 4Q Loss $30.9M; 18/04/2018 – TG Therapeutics: Clinical Trials Will Be Focused on Potential Synergism Between TG-1601 and Other Drugs in TG Pipeline; 26/03/2018 – TG Therapeutics Presenting at Conference Mar 28; 18/04/2018 – TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Company’s BET Inhibitor

Among 8 analysts covering TG Therapeutics (NASDAQ:TGTX), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. TG Therapeutics has $38.0 highest and $18 lowest target. $24.64’s average target is 78.55% above currents $13.8 stock price. TG Therapeutics had 23 analyst reports since August 12, 2015 according to SRatingsIntel. B. Riley & Co maintained the shares of TGTX in report on Friday, December 1 with “Buy” rating. The rating was initiated by SunTrust on Friday, May 27 with “Buy”. The stock of TG Therapeutics, Inc. (NASDAQ:TGTX) earned “Buy” rating by Suntrust Robinson on Friday, May 27. FBR Capital initiated the shares of TGTX in report on Tuesday, December 1 with “Outperform” rating. The stock of TG Therapeutics, Inc. (NASDAQ:TGTX) has “Hold” rating given on Wednesday, August 12 by Zacks. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, March 21. The stock of TG Therapeutics, Inc. (NASDAQ:TGTX) earned “Buy” rating by H.C. Wainwright on Tuesday, November 14. The stock of TG Therapeutics, Inc. (NASDAQ:TGTX) earned “Buy” rating by FBR Capital on Friday, March 9. The rating was reinitiated by H.C. Wainwright on Wednesday, August 12 with “Buy”. Jefferies maintained the stock with “Buy” rating in Monday, June 5 report.

Rivulet Capital Llc holds 6.97% of its portfolio in EVERTEC, Inc. for 3.74 million shares. Glenhill Advisors Llc owns 2.07 million shares or 3.87% of their US portfolio. Moreover, Philadelphia Financial Management Of San Francisco Llc has 1.83% invested in the company for 648,481 shares. The Massachusetts-based North Run Capital Lp has invested 1.61% in the stock. Continental Advisors Llc, a Illinois-based fund reported 359,647 shares.

Another recent and important EVERTEC, Inc. (NYSE:EVTC) news was published by Businesswire.com which published an article titled: “EVERTEC Launches Functionality for Non-Profits on ATH Móvil®” on June 13, 2018.

The stock increased 0.22% or $0.05 during the last trading session, reaching $22.65. About 200,626 shares traded. EVERTEC, Inc. (EVTC) has risen 31.52% since June 19, 2017 and is uptrending. It has outperformed by 18.95% the S&P500. Some Historical EVTC News: ; 01/05/2018 – Evertec Sees 2018 EPS $1.51-EPS $1.66; 05/03/2018 – S&PGR Takes Off Watch, Affirms EVERTEC Group ‘B+’ Ratings; 02/04/2018 – Fidelity Select Electronics Exits Evertec, Cuts Broadcom; 05/03/2018 S&P REVISES EVERTEC GROUP LLC OUTLOOK TO ‘STABLE’ FROM CREDIT WATCH ‘NEGATIVE’; RATING ‘B+’; 01/05/2018 – Evertec 1Q EPS 31c; 01/05/2018 – Evertec 1Q Rev $110.2M; 01/05/2018 – EVERTEC 1Q ADJ EPS 47C, EST. 31C; 04/04/2018 – Argentina’s Prisma piques Evertec’s interest, sources say [20:47 BST04 Apr 2018] [Proprietary] []; 01/05/2018 – EVERTEC 1Q REV. $110.3M, EST. $102.0M; 04/04/2018 – Argentina’s Prisma piques Evertec’s interest

TG Therapeutics, Inc. (NASDAQ:TGTX) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>